INDV (Pharmaceuticals) Stock Valuation & Fair Value Fairly valued
INDV (Pharmaceuticals) trades at a blended P/E of 12.4, about 12% above its historical normal valuation, with a forward growth estimate of 12.4% and a PEG of 1.00. Analysts' one-year estimates have been hit 27% of the time.
Valuation flags
- No notable valuation flags.
Frequently asked questions
Is INDV overvalued?
At a blended P/E of 12.4 versus its historical normal P/E of 11.1, INDV trades about 12% above its typical valuation, with a PEG of 1.00 on 12.4% forward growth. tickerseer currently rates it fairly valued.
What is INDV's fair value and PEG?
INDV trades at a blended P/E of 12.4 against a historical normal P/E of 11.1, a PEG of 1.00, and a forward growth estimate of 12.4%.
Has tickerseer's rating of INDV changed?
tickerseer's rating has been fairly valued since 2026-07-31.
Industry: Pharmaceuticals. Create a free account to see the full analysis: the SeerAI score, its five quality sub-scores, valuation history, and the AI research note. Options setups and metric history are part of the paid plans.
Get the free weekly earnings preview
One email each Monday with the week's named earnings setups, the reasoning, and what settled last week. Strikes and sizing stay in the paid plan.
It's free, and you can unsubscribe any time. Educational content, not investment advice.